Browsing Tag
Viking Therapeutics
6 posts
Eli Lilly (LLY) reclaims a $1tn valuation as Wall Street bets on its next weight-loss drug
Eli Lilly reclaimed a $1 trillion valuation at a record high as Wall Street prices in retatrutide, its next-gen obesity drug, and the GLP-1 metabolic platform thesis.
Viking Therapeutics’ GLP-1/GIP dual agonist VK2735 impresses at ObesityWeek 2025 with sustained weight-loss efficacy
Find out how Viking Therapeutics’ VK2735 is redefining obesity treatment with sustained clinical results — see what this breakthrough means for patients and investors today!
Why Viking Therapeutics (NASDAQ: VKTX) is gaining momentum before ObesityWeek 2025 reveals
Find out how Viking Therapeutics is positioning its obesity drug VK2735 for success as it readies data reveals at major 2025 medical conferences.
Which biotech companies are developing next-gen GLP-1 alternatives—and can they compete with Novo Nordisk and Eli Lilly by 2030?
Discover how biotech players like Viking, Structure, and Altimmune are developing next-gen GLP-1 drugs to challenge obesity leaders Novo Nordisk and Eli Lilly. Read more.
Wall Street turmoil: These 25 stocks plunged hardest amid Trump tariffs and sector shocks
Allegro MicroSystems, MP Materials, ZEEKR, and Albertsons led losses on April 15, 2025, as trade tensions, sector headwinds, and investor caution triggered a widespread selloff across US markets.
Viking Therapeutics initiates VOYAGE study for VK2809 in NASH
Viking Therapeutics has initiated the VOYAGE study, a phase 2b clinical trial of its liver-selective thyroid hormone receptor…